TyG Index Levels in Klinefelter Syndrome

NCT05014997 | Completed DMC

• 1 other identifier: GMS_21
• Study Type: observational
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

It is well known that the frequency of cardiometabolic diseases are increased in patients with Klinefelter Syndrome. The triglyceride-glucose index (TyG index) is a simple surrogate marker of insulin resistance and is also associated with various cardiometabolic diseases. The aim of this study to investigate the TyG index levels and its relationship with insulin resistance and endothelial dysfunction in patients with KS.

Conditions

Cardiac Event; Klinefelter Syndrome; Endothelial Dysfunction

Keywords

Klinefelter Syndrome, TyG Index, Cardiometabolic risk

Outcome Measures

Primary Outcomes (1)

• Cardiometabolic risk

  Triglyceride - Glucose Index

  1 day

Study Arms (2)

Patient

30 male patients with Klinefelter syndrome who were not previously given testosterone replacement.

Other: no intervention

Control

30 healthy control subject without diagnosis of any chronic disease

Other: no intervention

Interventions

no intervention OTHER

this study was designed as retrospective observational study

Control; Patient

Eligibility Criteria

• Age: 18 Years - 28 Years
• Gender Eligibility Details: We had a patient database consisting of male patients with Klinefelter syndrome
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

A total of 30 male patients with treatment-naive Klinefelter syndrome and 30 control subjects without any chronic disease

You may qualify if:

• Patients with a verified Klifelter Syndrome karyotype (all subjects included were 47, XXY) and who were not previously given testosterone replacement.

You may not qualify if:

• age \<18 years,
• acute infection, malignancy, any visceral organ dysfunction, nutritional derangements, clinical history of cardiovascular disease, cerebrovascular disease, drug use such as antidiabetic or lipid-lowering medications, or those lacking complete clinical data.

Sponsors & Collaborators

• Gulhane School of Medicine: lead

MeSH Terms

Conditions

Cardiovascular Diseases; Klinefelter Syndrome

Condition Hierarchy (Ancestors)

Sex Chromosome Disorders of Sex Development; Disorders of Sex Development; Urogenital Abnormalities; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Sex Chromosome Disorders; Chromosome Disorders; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Genetic Diseases, Inborn; Gonadal Disorders; Endocrine System Diseases; Hypogonadism

Study Officials

• Alper Sonmez, Prof.

  Health Sciences University, Gulhane School of Medicine, dep. of Endocrinology and Metabolism, Turkey

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr.

Study Record Dates

• First Submitted: August 16, 2021
• First Posted: August 20, 2021
• Study Start: February 10, 2013
• Primary Completion: October 1, 2014
• Study Completion: March 1, 2017
• Last Updated: August 20, 2021

Record last verified: 2021-08

Data Sharing

• IPD Sharing: Will not share